238 related articles for article (PubMed ID: 8455096)
41. Hygienic and toxicological aspects of occupational and environmental exposure to beryllium.
Bencko V; Vasil'eva EV
J Hyg Epidemiol Microbiol Immunol; 1983; 27(4):403-17. PubMed ID: 6663073
[TBL] [Abstract][Full Text] [Related]
42. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients.
Müller-Quernheim J; Gaede KI; Fireman E; Zissel G
Eur Respir J; 2006 Jun; 27(6):1190-5. PubMed ID: 16540500
[TBL] [Abstract][Full Text] [Related]
43. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease.
Weston A; Ensey J; Kreiss K; Keshava C; McCanlies E
Am J Ind Med; 2002 Jun; 41(6):457-65. PubMed ID: 12173370
[TBL] [Abstract][Full Text] [Related]
44. Beryllium: a paradigm for occupational lung disease and its prevention.
Kreiss K
Occup Environ Med; 2011 Nov; 68(11):787-8. PubMed ID: 21984591
[No Abstract] [Full Text] [Related]
45. A study on the beryllium lymphocyte transformation test and the beryllium levels in working environment.
Yoshida T; Shima S; Nagaoka K; Taniwaki H; Wada A; Kurita H; Morita K
Ind Health; 1997 Jul; 35(3):374-9. PubMed ID: 9248221
[TBL] [Abstract][Full Text] [Related]
46. Reexamination of the blood lymphocyte transformation test in the diagnosis of chronic beryllium disease.
Mroz MM; Kreiss K; Lezotte DC; Campbell PA; Newman LS
J Allergy Clin Immunol; 1991 Jul; 88(1):54-60. PubMed ID: 2071785
[TBL] [Abstract][Full Text] [Related]
47. Beryllium disease among construction trade workers at Department of Energy nuclear sites.
Welch LS; Ringen K; Dement J; Bingham E; Quinn P; Shorter J; Fisher M
Am J Ind Med; 2013 Oct; 56(10):1125-36. PubMed ID: 23794247
[TBL] [Abstract][Full Text] [Related]
48. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility.
Stange AW; Hilmas DE; Furman FJ; Gatliffe TR
Appl Occup Environ Hyg; 2001 Mar; 16(3):405-17. PubMed ID: 11297055
[TBL] [Abstract][Full Text] [Related]
49. Pathologic and immunologic alterations in early stages of beryllium disease. Re-examination of disease definition and natural history.
Newman LS; Kreiss K; King TE; Seay S; Campbell PA
Am Rev Respir Dis; 1989 Jun; 139(6):1479-86. PubMed ID: 2729754
[TBL] [Abstract][Full Text] [Related]
50. Beryllium induces IL-2 and IFN-gamma in berylliosis.
Tinkle SS; Kittle LA; Schumacher BA; Newman LS
J Immunol; 1997 Jan; 158(1):518-26. PubMed ID: 8977230
[TBL] [Abstract][Full Text] [Related]
51. Screening for chronic beryllium disease: one hurdle down, two to go.
Cullen MR
Am J Respir Crit Care Med; 2005 Jan; 171(1):3-4. PubMed ID: 15615889
[No Abstract] [Full Text] [Related]
52. Beryllium sensitivity among workers at a Norwegian aluminum smelter.
Nilsen AM; Vik R; Behrens C; Drabløs PA; Espevik T
Am J Ind Med; 2010 Jul; 53(7):724-32. PubMed ID: 20187010
[TBL] [Abstract][Full Text] [Related]
53. Significance of the blood beryllium lymphocyte proliferation test.
Newman LS
Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):953-6. PubMed ID: 8933041
[TBL] [Abstract][Full Text] [Related]
54. Prevention of beryllium sensitization and chronic beryllium disease.
Henneberger PK; Goe SK; Miller WE; Doney B; Groce DW
J Occup Environ Hyg; 2006 Apr; 3(4):D42-3. PubMed ID: 16507518
[No Abstract] [Full Text] [Related]
55. Long-term follow-up of beryllium sensitized workers from a single employer.
Duggal M; Deubner DC; Curtis AM; Cullen MR
BMC Public Health; 2010 Jan; 10():5. PubMed ID: 20047684
[TBL] [Abstract][Full Text] [Related]
56. Sensitization and chronic beryllium disease at a primary manufacturing facility, part 2: validation of historical exposures.
Park JY; Virji MA; Stefaniak AB; Stanton ML; Day GA; Kent MS; Schuler CR; Kreiss K
Scand J Work Environ Health; 2012 May; 38(3):259-69. PubMed ID: 21847507
[TBL] [Abstract][Full Text] [Related]
57. A novel alternative to environmental monitoring to detect workers at risk for beryllium exposure-related health effects.
Fireman E; Lerman Y; Stark M; Pardo A; Schwarz Y; Van Dyke MV; Elliot J; Barkes B; Newman L; Maier L
J Occup Environ Hyg; 2014; 11(12):809-18. PubMed ID: 24856577
[TBL] [Abstract][Full Text] [Related]
58. A model for optimization of biomarker testing frequency to minimize disease and cost: example of beryllium sensitization testing.
Judd NL; Griffith WC; Takaro T; Faustman EM
Risk Anal; 2003 Dec; 23(6):1211-20. PubMed ID: 14641896
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of a program to prevent beryllium sensitization among new employees at a copper-beryllium alloy processing facility.
Thomas CA; Bailey RL; Kent MS; Deubner DC; Kreiss K; Schuler CR
Public Health Rep; 2009; 124 Suppl 1(Suppl 1):112-24. PubMed ID: 19618813
[TBL] [Abstract][Full Text] [Related]
60. Misdiagnosis of sarcoidosis in patients with chronic beryllium disease.
Fireman E; Haimsky E; Noiderfer M; Priel I; Lerman Y
Sarcoidosis Vasc Diffuse Lung Dis; 2003 Jun; 20(2):144-8. PubMed ID: 12870725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
